Download Sharing on Campus Berlin-Buch

Biotechnology Common
Tools
Presentation on Shared Facilities
Turin, 19th February 2010
Service and Support
for Biotechnology in Berlin-Brandenburg
Agenda
1. Regional Sharing: Opportunities and
restraints
2. Sharing on Campus Berlin-Buch:
Research-Clinics-Biotech
3. Example of sharing practice: FMP
Screening Unit
Opportunities for
sharing in BerlinBrandenburg
Potential sharing
Industry/SMEs
No incubator offering space,
money and
know how
Space (Bio Parks)
Large-scale facilities
Some but difficult
cooperation;
fee for service
Ethical issues?
Biomaterials
Animal facilities
Know-how
Science
Little cooperation; own
equipment
Almost no sharing of experts
between companies (except
for IT)
Regional
Biotechnology Parks
BioTechnologieZentrum Hennigsdorf
Campus Berlin-Buch
Berlin Adlershof
berlinbiotechpark
Potsdam Biotech Campus
Biotechnologiepark Luckenwalde
Identified (largescale) Facilities
Name
E1
FEM Animal Facilities
E2
Synchroton BESSY II storage ring
E3
Centre for Biomaterial Development
E4
Clinical research unit of the Charité Research
Organisation (CRO)
E5
Competence Center for Clinical Studies
E6
Experimental and Clinical research Center (ECRC)
E7
FMP screening Unit
E8
Green house facilities – Potsdam University
E9
Max-Planck-Institute –screening of RNA
E 10
Platform for transnational research
E 11
Ultra structure network
Agenda
1. Regional Sharing: Opportunities and
restraints
2. Sharing on Campus Berlin-Buch:
Research-Clinics-Biotech
3. Example of sharing practice: FMP
Screening Unit
Campus Berlin-Buch
 A modern science, health and biotechnology park with a
clear focus on biomedicine and 2,200 employees on 32
hectares
 Unique environment for scientific exchange and research
collaboration, facilitated by the close physical proximity of
- research institutes
- clinics
- biotechnology companies
 Major areas of activity include
- study of the molecular causes of cancer
-
cardiovascular and neurodegenerative diseases
interdisciplinary basic research to develop new drugs
patient-oriented clinical research
commercial realization of biomedical insights
 Investments of more than 200 million euros from the federal
government, state government and the EU
Innovative location
with an attractive
infrastructure and
international flair
Concept
 High quality of living and working
-
closeness of the institutions to each other
-
setting in a beautiful park landscape
-
communicative places to eat, guesthouses,
 Health Region
fast connection to Berlin‘s cultural life
-
direct proximity to the lakes and forests
provides numerous opportunities for
kindergarten, research library
-
-
leisure and recreation
synergy between science and art with
sculpture park, exhibitions and a museum
 Events
 Communication & Information
Max Delbrück Communications Center
„Long Night of the Sciences“
-
one of the most modern congress centers in Berlin
-
-
serves as an international meeting place for
-
In June welcomes thousands of visitors
annually
researchers and physicians as well as an arena for
gives insight into the biosciences and medicine
active social discourse
in an entertaining way through participatory
CampusInfoCenter
courses, lab tours, "science comedy" and
-
information booths
Located in the same historic building as the Life
Science Learning Lab
-
popular with visitors and guests of the Campus as
a place to meet and obtain information
Structure and on-site
facilities
Basic
Research
Institutes
Clinical
Research
Institutes
Maximum-care
clinics
BiotechPark


Max Delbrück Center for Molecular Medicine
(MDC)
Leibniz Institute for Molecular Pharmacology
(FMP)


Robert Rössle Clinic for Tumor Diseases
(RRK)
Franz Volhard Clinic for Cardiovascular
Deseases (FVK)






HELIOS Clinic Berlin-Buch
Evangelische Lungenklinik Berlin (ELK)
Rheuma Clinic Berlin-Buch
All organized as private-enterprise entities
Approximately 40 companies in 2009
Amongst others Silence Therapeutics,
Glycotope, ImaGenes, Invitek, Bavarian
Nordic
Outstanding innovation
and growth potential
through value-creating
synergies
Research Institutes:
MDC & FMP
Structure
Research
objectives
- One of 15 institutions of the Hermann von
- Along with seven additional Berlin Leibniz
Helmholtz Association of German Research
Institutes it is administratively integrated into
Centers (HGF)
the Berlin Research Association
- Undertakes modern biomedical and clinical
- Main research areas are the elucidation of the
research to develop scientifically-based methods structure, function and the interactions of
of diagnosis, therapy and prevention
proteins as well as the identification of small
molecules (agents)
- Scientists utilize molecular-biological and gene- - Makes scientific contributions in the first
Methods
technological methods in order to analyze
preliminary stages of drug development by
complex diseases
bringing together pharmacological basic
research and the development of new drugs
- Close cooperation with two specialist clinics - Many cooperation agreements with national
(Robert Rössle Clinic for Tumor Diseases and the and international research institutes and with
Franz Volhard Clinic for Cardiovascular Diseases) industry
Cooperations
- Closely affiliated with the universities in
Berlin due to five joint chairs, participation in
teaching and diverse cooperations, e.g. within
the scope of association research projects
Biotech Park
Infrastructure



Approximately 26,000 m² of sector-specific lab and office space is available to
founders and companies under attractive conditions
Additional sites for building on the Campus offer options for development over
the middle and long term
A tradition of excellence in molecular medical basic research and clinical
research as well outstanding maximum care for patients make the BiotechPark


Berlin an ideal environment
The creative atmosphere of the Campus promotes know-how exchange,
technology transfer and joint projects
Managed by BBB Managment GmbH Campus Berlin-Buch being responsible
for coordinating the development of the entire site
Companies


At present approximately 47 biotechnology companies are located on the
Campus with a total of 750 employees
The spectrum of business fields includes
-
medical-technical products
-
molecular diagnostics and therapies
preclinical pharmacological and pharmacogenomics tests
-
RNA technologies
the search for pharma-relevant target molecules
-
production and testing of drugs under the specifications of (GMP)
analysis and synthesis of biomolecules
Proximity of facilities
HELIOS
Genomhaus
(FMP & MDC)
BiotechPark
MDC
FMP
Agenda
1. Regional Sharing: Opportunities and
restraints
2. Sharing on Campus Berlin-Buch:
Research-Clinics-Biotech
3. Example of sharing practice: FMP
Screening Unit
The Leibniz Institute
for Molecular
Pharmacology (FMP)
Facts & figures




258 staff (08/08)
163 research scientists
Budget 2008: 19 Mio Euro
5.8 Mio Euro external funding (total in 2008)
Research sections & focus


Sections: Chemical Biology, Structural Biology, Signal Transduction/ Molecular Genetics
Focus:
-
Structure and function of proteins
New approaches to modulating protein function
Identification of small molecules as chemical, diagnostic and therapeutic tools
Identification of biological macromolecules as drug targets
Mission


Scientific Mission:
-
40.000 currently available drugs act through 324 structures (proteins)
Up to 10.000 structures are considered drug targets (proteins)
Goal: broaden the basis of drug therapy!
Organisational Mission:
-
Improve conditions for drug-related research and drug development by
promoting interdisciplinary projects that combine chemical biological approaches (Chemical Biology)
establishing drug discovery and development networks (public-private partnerships, national and
international scale)
Screening at the FMP
Screening Unit
Open Access
HTS
Screening Robot
Automatic Microscope
 Projects on not (yet) validated targets
 Development of chemical toos for the investigation of

protein functions, diagnostic substances and drugs
Open platform for academic partners and SME
Featured
technologies of
screening unit
in silico screening
online database
Process Automation
unique technologies
Screening Unit
Open Access HTS
LabChip
compound libraries
Automated
microscopes
Sharing of screening
facility
Open Access Screening Platform (> 80 projects since 2004)
Yale University, Craig Crews
University of Oxford, S. Knapp
MRC Cambridge, E. Gherardi & T. Blundel
University of Glasgow, E. Munroe
Biotechnology Center Oslo, Kjetil Tasken
University of Oslo, S. Strauss
Karolynska Institute, S. Strömblad
University Göteborg, S. Trybala
Vanderbilt University, M. Waterman
UCSF, L. Podust
EMBL-Hamburg, M. Willmanns
MPI-Dortmund, C. Ottmann
Max-Planck-Group Hamburg, E. Mandelkow
Max-Planck-Group Hamburg, H. Bartunik
ZMNH Hamburg, M. Schachner
TU München, J. Ruland
Universität Leipzig, M. Schäfer
Universität Frankfurt, R. Stauber
Universität Rostock, Thiesen
Universitätsklinik Marburg, T. Gress
Bayer Schering Pharma, A. Sommer
NDDI (Novartis, Boston, G. Petrella)
Wnt-antagonists:
Metastasis
European screening
activities
EU-OPENSCREEN





A European Infrastructure of Open Screening
Platforms for Chemical Biology
A distributed infrastructure open for transnational
access
Will be used by researchers from universities and
research institutes who have either only limited inhouse facilities or no access at all to such an
infrastructure
Will accelerate the generation of knowledge on the
bioactivities of chemicals as well as on the responses
of biological systems
Unlike commercial screening platforms and
pharmaceutical industry EU-OPENSCREEN will
address non-validated targets
EU-OPENSCREEN
network*
Coordination Centre at FMP Berlin
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
Sweden – Univ. Umeå
Finland – FIMM Nordic EMBL Helsinki
Poland – IMB, Lodz
Hungary – Univ. Budapest
Czech Rep. – Inst. Molecular Genetics
Prague
Austria – CeMM Wien
Italy – CISI Milano
Switzerland – Ecole Polytechn. Féd.
Lausanne
Spain – Barcelona Science Parc,
Portugal – Univ. Lisbon
France – Univ. Strasbourg
Netherlands – NKI Amsterdam
European Bioinformatics Institute (EBI)
UK – Univ. Dundee,
Univ. Cambridge
Denmark – Univ. Copenhagen
Norway – Univ. of Oslo
Greece – BRFAA Athens
2
16
1
15
14
3
13
12
5
11
6
4
8
7
10
9
17
*Important remark: This list shows the current network, which is not necessarily identical with the institutions participating in the PP.
Contact Details
Thank you for your attention!
Wolfgang Korek
BioTOP Berlin-Brandenburg
Fasanenstraße 85
10623 Berlin
Tel: + 49 30 3186-2218
[email protected]
www.biotop.de